Market Survey on Gene Therapy in CNS Disorder Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Gene Therapy in CNS Disorder Market including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, and Batten Disease Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Gene Therapy in CNS Disorder Market Snapshot (2023 to 2033)
The global gene therapy in CNS disorder market is expected to garner a market value of US$ 8.2 Billion in 2023 and is expected to accumulate a market value of US$ 113.04 Billion by registering a CAGR of 30% in the forecast period 2023 to 2033. The market for gene therapy in CNS disorders registered a CAGR of 19% in the historical period 2018 to 2022.
The gene therapy market for CNS disorders is rapidly growing, with a focus on delivering therapeutic genes directly to the brain to treat neurological conditions. The Gene Therapy in CNS Disorder market is a segment of the healthcare industry that deals with the effective management of the condition. The Gene Therapy in CNS Disorder market offers a range of products and services for its effective management and treatments. The most common CNS disorders being targeted by gene therapy include Parkinson's disease, Alzheimer's disease, Spinal Muscular Atrophy (SMA), Huntington's disease, and ALS (Amyotrophic Lateral Sclerosis).
Data Points
Key Statistics
Expected Market Value (2023)
US$ 8.2 billion
Anticipated Forecast Value (2033)
US$ 113.04 billion
Projected Growth Rate (2023 to 2033)
30% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Gene Therapy in CNS Disorder Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for gene therapy in CNS disorder reflected a value of 19% during the historical period, 2018 to 2022. During this period, the demand for gene therapy for CNS disorders increased due to the rising prevalence of these disorders, advancements in gene therapy technology, increasing awareness among healthcare providers and patients, and regulatory support. The market for Gene Therapy in CNS Disorder is gaining prominence as several companies are investing heavily in research and development of these therapies, resulting in the development of new treatment options for conditions such as Parkinson's disease, Alzheimer's disease, SMA, and ALS.
Looking ahead to the period from 2023 to 2033, the gene therapy market for CNS disorders is expected to continue growing. The increasing prevalence of CNS disorders and the rising demand for effective treatments are expected to drive demand for gene therapy in this space. Furthermore, the increasing investment in research and development of gene therapy for CNS disorders, along with the increasing regulatory support, is expected to result in the development and approval of more gene therapies for these conditions.
Overall, the gene therapy market for CNS disorders is expected to experience strong demand from 2023 to 2033, driven by several factors such as the increasing prevalence of these conditions, advancements in technology, growing awareness, and regulatory support. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies are creating awareness of Gene Therapy in CNS Disorder, fuelling the market growth. Thus, the market for Gene Therapy in CNS Disorder is expected to register a CAGR of 30% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Gene Therapy in the CNS Disorder Market?
Growing advancements in diagnostic and treatment options to push the market growth
The global gene therapy in CNS disorder market is primarily driven by an increased prevalence of CNS disorders such as, such as Parkinson's disease, Alzheimer's disease, and ALS, which is on the rise, which is driving the demand for effective treatments.
Up to 1 billion people, nearly one in six of the world’s population, suffer from neurological disorders, from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy to migraine, brain injuries and neuroinfections, with some 6.8 million dying of the maladies each year, according to a new United Nations report.
There have been significant advancements in gene therapy technology, including the development of viral vectors that can deliver therapeutic genes to the brain more efficiently and safely. Additionally, the growth of the Gene Therapy in CNS Disorder market is owed to ongoing research and development, which is leading to an increased potential for new and improved treatment options to become available for patients with CNS disorders. There is a growing investment in research and development of gene therapy for CNS disorders, with many biotech and pharmaceutical companies working on developing new gene therapies for these conditions.
For instance, in June 2021, Alcyone Therapeutics announced its launch and receipt of $23 million in funding from funds affiliated with RTW Investments, LP. Alcyone is a biotechnology company dedicated to developing precision therapies for severe neurological conditions that impact patients and their families. Alcyone partnered with the Abigail Wexner Research Institute at Nationwide Children's Hospital to combine its proprietary next-generation CNS delivery platform and product development, manufacturing, and commercialization capabilities with AWRI's four gene therapy technologies and research and early development capabilities.
As more effective treatments become available, patients with CNS may experience better health outcomes and quality of life. This could increase demand for management options and further drive market growth.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by Gene Therapy in the CNS Disorder Market?
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by challenging factors such as Complexity of delivery, Immune responses, Safety concerns, Regulatory challenges, and Ethical considerations. Delivering therapeutic genes to the brain is a complex process, as the blood-brain barrier can prevent the delivery of gene therapy vectors to the targeted cells in the brain. The development of efficient delivery systems that can overcome this challenge is crucial for the success of gene therapy in CNS disorders.
Furthermore, gene therapy raises several ethical considerations, including the potential for unintended consequences or the development of genetic enhancements that may have social and ethical implications. Additionally, regulatory hurdles can limit the speed of development and availability of gene therapy treatments for CNS disorders.
Region-Wise Insights
How is the Gene Therapy in CNS Disorder Market Turning Out in the South & East Asian Region?
Increasing Focus on R&D Shaping Landscape for Gene Therapy in CNS Disorders
The gene therapy market for CNS disorders is still in its early stages in the South and East Asian regions, but there is increasing interest in this field and several companies are actively engaged in research and development of gene therapies for CNS disorders in these regions. The South & East Asia region is expected to exhibit the significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period.
The regulatory landscape for gene therapy in the South and East Asian region is evolving, with several countries adopting guidelines for the approval and regulation of gene therapy. For example, the Indian Council of Medical Research (ICMR) recently released guidelines for the ethical, legal and regulatory aspects of gene therapy research and clinical trials in India.
What are the Factors Boosting the Market for Gene Therapy in CNS Disorder in North America?
Increasing Focus on Technological Advancements shaping Landscape for Gene Therapy in CNS Disorder in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the high prevalence of CNS disorders in North America, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, which has led to a strong demand for new treatments. Additionally, North America has a well-developed healthcare infrastructure, along with a high level of research and development, significant investment, and a supportive regulatory environment.
The United States of America, in particular, has been experiencing an increase in CNS disorders related deaths, which may drive demand for treatment. The United States of America holds the highest share in the North American market, followed by Canada. Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, and high level of healthcare expenditure leading to a large patient population are some of the factors responsible for the growth of the market in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By Indication, Which Segment is Likely to Account for a Significant Share?
Alzheimer’s disease to hold a significant share and push market growth
According to Future Market Insights, Alzheimer's disease, in particular, is likely to account for a significant share of the gene therapy in CNS disorders market. This is due to the high prevalence of neurodegenerative disorders.
Alzheimer's disease is a progressive and incurable neurodegenerative disorder that affects millions of people worldwide. It is the most common cause of dementia in the elderly, and the prevalence of the disease is expected to rise in the coming years due to an aging population.
By End User, Which Segment is Likely to Account for a Significant Share?
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the gene therapy in CNS disorder treatment facilitates the growth of this segment.
Majority of the serious diseases involving the nervous system are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Market Competition
Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.
In November 2022, a team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.
In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson's disease.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 8.2 billion
Market Value in 2033
US$ 113.04 billion
Growth Rate
CAGR of 30% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Type
Indication
End-Users
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Voyager Therapeutics
Spark Therapeutics
Novartis AG
Bluebird Bio Inc.
Biogen
Pfizer Inc.
Rapa Therapeutics
BrainStorm Cell Therapeutics
Eli Lily and Company
UniQure Biopharma
Customization
Available Upon Request
Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey
Indication:
Alzheimer's Disease
Huntington's Disease
Parkinson's Disease
Batten Disease
Type:
Ex Vivo
In Vivo
End User:
Hospitals
Speciality Clinics
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
How Big is the Gene Therapy in CNS Disorder Market?
The market is valued at US$ 8.2 billion in 2023.
Who are the key Market Players?
Novartis AG, Bluebird Bio Inc., and Biogen are key market players.
What is the growth forecast for the Market?
The market is forecast to register a CAGR of 30.0% through 2033.
What is the North America’s expected share in 2033?
North America is likely to generate 40% revenue in 2033.
Which is the top trend in the Market?
Significant advancements in gene therapy technology is encouraging the market growth.
Table of Content
1. Executive Summary | Gene Therapy in CNS Disorder Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
5.3.1. Alzheimer's Disease
5.3.2. Huntington's Disease
5.3.3. Parkinson's Disease
5.3.4. Batten Disease
5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
6.3.1. Ex Vivo
6.3.2. In Vivo
6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End Users , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.4. Y-o-Y Growth Trend Analysis By End Users , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End Users , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Indication
9.2.3. By Type
9.2.4. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Indication
9.3.3. By Type
9.3.4. By End Users
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Indication
10.2.3. By Type
10.2.4. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Indication
10.3.3. By Type
10.3.4. By End Users
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Indication
11.2.3. By Type
11.2.4. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Indication
11.3.3. By Type
11.3.4. By End Users
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Indication
12.2.3. By Type
12.2.4. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Indication
12.3.3. By Type
12.3.4. By End Users
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Indication
13.2.3. By Type
13.2.4. By End Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Indication
13.3.3. By Type
13.3.4. By End Users
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Indication
14.2.3. By Type
14.2.4. By End Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Indication
14.3.3. By Type
14.3.4. By End Users
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Indication
15.2.3. By Type
15.2.4. By End Users
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Indication
15.3.3. By Type
15.3.4. By End Users
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Indication
16.1.2.2. By Type
16.1.2.3. By End Users
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Indication
16.2.2.2. By Type
16.2.2.3. By End Users
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Indication
16.3.2.2. By Type
16.3.2.3. By End Users
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Indication
16.4.2.2. By Type
16.4.2.3. By End Users
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Indication
16.5.2.2. By Type
16.5.2.3. By End Users
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Indication
16.6.2.2. By Type
16.6.2.3. By End Users
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Indication
16.7.2.2. By Type
16.7.2.3. By End Users
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Indication
16.8.2.2. By Type
16.8.2.3. By End Users
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Indication
16.9.2.2. By Type
16.9.2.3. By End Users
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Indication
16.10.2.2. By Type
16.10.2.3. By End Users
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Indication
16.11.2.2. By Type
16.11.2.3. By End Users
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Indication
16.12.2.2. By Type
16.12.2.3. By End Users
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Indication
16.13.2.2. By Type
16.13.2.3. By End Users
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Indication
16.14.2.2. By Type
16.14.2.3. By End Users
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Indication
16.15.2.2. By Type
16.15.2.3. By End Users
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Indication
16.16.2.2. By Type
16.16.2.3. By End Users
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Indication
16.17.2.2. By Type
16.17.2.3. By End Users
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Indication
16.18.2.2. By Type
16.18.2.3. By End Users
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Indication
16.19.2.2. By Type
16.19.2.3. By End Users
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Indication
16.20.2.2. By Type
16.20.2.3. By End Users
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Indication
16.21.2.2. By Type
16.21.2.3. By End Users
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Indication
17.3.3. By Type
17.3.4. By End Users
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Voyager Therapeutics
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Spark Therapeutics
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Novartis AG
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Bluebird bio, Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Biogen
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Pfizer Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Rapa Therapeutics
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. BrainStorm Cell Therapeutics
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Eli Lilly and Company
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. UniQure Biopharma
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Indication, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by End Users , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Indication, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End Users , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 17: Global Market Attractiveness by Indication, 2023 to 2033
Figure 18: Global Market Attractiveness by Type, 2023 to 2033
Figure 19: Global Market Attractiveness by End Users , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End Users , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 37: North America Market Attractiveness by Indication, 2023 to 2033
Figure 38: North America Market Attractiveness by Type, 2023 to 2033
Figure 39: North America Market Attractiveness by End Users , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Indication, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End Users , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Indication, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End Users , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Indication, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by End Users , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 77: Europe Market Attractiveness by Indication, 2023 to 2033
Figure 78: Europe Market Attractiveness by Type, 2023 to 2033
Figure 79: Europe Market Attractiveness by End Users , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Indication, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Type, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by End Users , 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 97: South Asia Market Attractiveness by Indication, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Type, 2023 to 2033
Figure 99: South Asia Market Attractiveness by End Users , 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Indication, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Type, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by End Users , 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 117: East Asia Market Attractiveness by Indication, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Type, 2023 to 2033
Figure 119: East Asia Market Attractiveness by End Users , 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Indication, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Type, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by End Users , 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 137: Oceania Market Attractiveness by Indication, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Type, 2023 to 2033
Figure 139: Oceania Market Attractiveness by End Users , 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Indication, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Type, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by End Users , 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Indication, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by End Users , 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033
Figure 157: MEA Market Attractiveness by Indication, 2023 to 2033
Figure 158: MEA Market Attractiveness by Type, 2023 to 2033
Figure 159: MEA Market Attractiveness by End Users , 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
